Patents by Inventor Lilli Anselm

Lilli Anselm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210277020
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using the compounds and methods of determining the monoacylglycerol lipase (MAGL) inhibitory activity of the compounds.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 9, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lilli ANSELM, Joerg BENZ, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dominik HEER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Fionn O`HARA, Hans RICHTER
  • Patent number: 9896438
    Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: February 20, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Lilli Anselm, Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Haap Wolfgang, Jens-Uwe Peters, Thomas Woltering, Ulrike Obst Sander, Mark Rogers-Evans
  • Patent number: 9409882
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: August 9, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lilli Anselm, David Banner, Wolfgang Haap, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters, Beat Spinnler
  • Patent number: 9290467
    Abstract: The invention relates to a compound of formula (I) wherein A, B, D and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: March 22, 2016
    Assignee: HOFFMANN—LA ROCHE INC.
    Inventors: Lilli Anselm, David Banner, Jean-Baptiste Blanc, Delphine Gaufreteau, Wolfgang Haap, Guido Hartmann, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters, Beat Spinnler
  • Publication number: 20150307472
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: February 20, 2015
    Publication date: October 29, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lilli Anselm, David Banner, Wolfgang Haap, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters, Beat Spinnler
  • Patent number: 8822505
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1 to R8 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: September 2, 2014
    Assignee: Genentech, Inc.
    Inventors: Lilli Anselm, David Banner, Wolfgang Haap, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters, Beat Spinnler
  • Patent number: 7601752
    Abstract: The invention is concerned with novel pyrrolidine derivatives of formula (I) wherein X, Y, R1, R2 and R3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: October 13, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lilli Anselm, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Bernd Kuhn, Narendra Panday, Fabienne Ricklin, Stefan Thomi
  • Patent number: 7550487
    Abstract: The invention is concerned with novel pyrrolidine-3,4-dicarboxamide derivatives of formula (I) wherein R1 to R9 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: June 23, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lilli Anselm, Katrin Groebke Zbinden, Wolfgang Haap, Jacques Himber, Christoph Martin Stahl, Stefan Thomi
  • Publication number: 20070112001
    Abstract: The invention is concerned with novel pyrrolidine derivatives of formula (I) wherein X, Y, R1, R2 and R3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Application
    Filed: November 6, 2006
    Publication date: May 17, 2007
    Inventors: Lilli Anselm, Katrin Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Bernd Kuhn, Narendra Panday, Fabienne Ricklin, Stefan Thomi
  • Publication number: 20050215599
    Abstract: The invention is concerned with novel pyrrolidine-3,4-dicarboxamide derivatives of formula (I) wherein R1 to R9 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof.
    Type: Application
    Filed: March 9, 2005
    Publication date: September 29, 2005
    Inventors: Lilli Anselm, Katrin Zbinden, Wolfgang Haap, Jacques Himber, Christoph Stahl, Stefan Thomi